A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma

Purpose

Primary Objective: To compare disease-free survival (DFS) between subjects randomized to nab-paclitaxel in combination with gemcitabine and subjects randomized to gemcitabine alone. Secondary Objectives: 1. To assess overall survival (OS) between subjects randomized to nab-paclitaxel in combination with gemcitabine and subjects randomized to gemcitabine alone 2. To assess safety and tolerability of the 2 treatment regimens

Keywords

disease-free survival, nab-paclitaxel, gemcitabine, treatment, safety

Principal Investigator

Thomas J George, M.D.

Department

HEMATOLOGY AND ONCOLOGY

Contact Information

tgeorge@ufl.edu
3522738008

Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at CTSI-Studies-L@lists.ufl.edu.

Other Resources

  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams